celg report financi consensu driven strong sale perform across
franchis celgen pipelin mileston remain track ozanimod re-fil
liso-cel bla submit pivot karmma trial
fulli enrol price target cut reflect acquisit offer
celgen report financi beat consensu top bottom line sale
compani key franchis least in-lin consensu revlimid
pomalyst vs total product sale grew y/i driven volum
gain y/i price fx impact total revenu quarter
drove non-gaap ep consensu estim
respect guidanc reiter initi announc
earlier month includ total revenu y/i midpoint
non-gaap ep y/i midpoint celgen also re-affirmed
goal total revenu non-gaap ep greater
januari bristol-my market perform scala announc
intent acquir celgen cash stock transact valu celg
sharehold receiv one bm share cash per celg share addit
celg sharehold receiv conting valu right cvr celg share whose
valu depend futur regulatori mileston holder entitl onetim
payment ozanimod liso-cel approv decemb
approv march acquisit expect close
base today price estim current valu cvr
today cut celg price target reflect
given bmi offer celg expect close perhap import
near-term earn would develop could put deal risk
promin would materi advers develop revlmid patent disput
particularli dr reddi expect pto decid whether institut dr
reddi ipr challeng revlimid md use patent februari therefor
decis ipr would come februari notabl three patent
subject dr reddi ipr challeng claim use revlimid treat md order
launch dr reddi would need invalid demonstr infring
revlimid orang book list patent notabl revlimid polymorph patent
therefor matter result ipr process believ dr reddi would still need
prevail district court case subsequ appeal celgen judg
dr reddi case recent move case mediat phase yet
schedul assum mediat lead settlement celgen expect district
court case render verdict late earli appeal last addit
month impli verdict mid-to-l thu would appear unlik
advers decis dr reddi disput would render prior close
pleas see page report import disclosur
januari bristol-my squibb announc intent acquir celgen
share cash tradabl cvr potenti worth certain
mileston met share celg celgen lead biotechnolog compani
franchis treatment cancer inflammatori disord compani
pioneer develop commerci imid class drug
demonstr great util treat myeloma condit celgen
import franchis revlimid sale appear pois continu
growth part base upon label expans increas combin use newli
regulatori submiss ozanimoid
regulatori submiss luspatercept
md beta-th
expect close bms-celg deal
revlimid continu grow steadi
pace achiev peak
revenu
otezla achiev sale
bms-celg deal close
contribut meaning futur
otezla succe new indic
revenu earn fall short
revlimid ip fall challeng
bms-celg deal close plan
celg one largest biotechnolog compani franchis treatment
cancer inflammatori disord revlimid multipl myeloma sale
y/i appear pois continu growth base upon label expans use
combin newer therapi celgen top-lin becom increasingli diversifi
recent year pomalyst refractori myeloma sale y/i benefit
trend revlimid otezla approv psoriasi drove sale
y/i abraxan sale y/i continu post solid sale
base upon success pancreat cancer remain key pipelin asset includ ozanimod
ms resubmit regulatori packag fedratinib mf submit fda
bluebird anti-bcma car-t pivot studi file acceleron
luspatercept md beta thalassemia regulatori file anticip
luspatercept celgen remain track submit eu regulatori file use
rs md transfusion-depend beta-thalassemia data phase ii studi
myelofibrosi anticip celgen think luspatercept could gener
md beta-th alon without factor mf opportun
ozanimod celgen remain on-track resubmit ozanimod nda submit
eu rm manag indic non-clin bridg studi
pk/pd ddi trial complet resubmit packag also includ anoth
year safeti data manag believ strengthen submiss enrol
phase studi ozanimod uc complet phase studi crohn
continu enrol
fedratinib nda submit fedratinib myelofibrosi potenti approv
anticip eu submiss expect celgen plan
initi phase i/ii studi combin luspatercept manag see
fedratinib opportun
celgen partner bluebird bio complet enrol pivot
karmma studi anti-bcma car-t patient highli refractori mm
 approv indic anticip base cadenc data
regulatori submiss clinic investig earlier line therapi continu
advanc initi phase ii studi ndmm expect
liso-cel celgen continu collect follow-up data transcend studi
liso-cel r/r dlbcl bla submiss indic expect lead
potenti approv manag plan initi pivot ph ii studi liso-cel
r/r cll btk failur
outsid product celgen continu expand exist franchis regulatori
packag submit revlimid r/r fl part regimen pdufa
date expect pdufa date juli set otezla behcet
diseas eu submiss plan snda submiss scalp psoriasi
expect pdufa date also set combin use abraxan
roch atezolizumab mtnbc march mnsclc septemb
januari bristol-my squibb announc intent acquir celgen
share cash tradabl cvr potenti worth certain
mileston met share celg celgen lead biotechnolog compani
franchis treatment cancer inflammatori disord compani
pioneer develop commerci imid class drug
demonstr great util treat myeloma condit celgen
import franchis revlimid sale appear pois continu
growth part base upon label expans increas combin use newli
diagnos multipl myeloma celgen top line becom increasingli diversifi
recent year pomalyst refractori myeloma sale y/i also
benefit combin use myeloma safe oral drug otezla serv uniqu
nich psoriasi sale y/i abraxan sale
y/i continu post solid sale base upon success pancreat cancer though
growth abat addit number collabor acquisit
allow celgen materi strengthen pipelin launch idhifa partner
agio solid follow august approv model
sale celgen acquir gain access
engin t-cell-bas therapi remain key pipelin asset includ ozanimod
ms resubmit regulatori packag uc phase partial right
hematolog malign phase ii fedratinib mf
submit fda bluebird anti-bcma car-t pivot studi
file acceleron luspatercept md beta thalassemia regulatori
file anticip
cowen compani
reportedcowen estimateu total product total oper cowen
phase robust data patient dlbcl
pdufa date regimen r/r nhl
pdufa date atezo abraxan mtnbc
phase apact data abraxan adjuv pancreat cancer
submiss fedratinib myelofibrosi
pdufa date atezo abraxan mnsclc
bla submiss liso-cel nhl
potenti approv fedratinib myelofibrosi
resubmiss ozanimod nda submiss rrm
submit snda otezla scalp psoriasi
submit otezla behcet
complet enrol phase studi ozanimod uc
pdufa date otezla behcet
complet enrol phase ii studi sle
regulatori submiss luspatercept md beta-thalassemia
initi ph ii trial ndmm
phase ii luspatercept data myelofibrosi
potenti approv highli refractori mm
cowen compani
cowen compani
 ww total hematolog y/i total oncolog others- total product revenu includ gross total total incom excl ep tax incom incl stock-bas ep includ stock share outstand ep exclud merger-rel item stock compens upfront-mileston payment item ep cowen
cowen compani
 ww hematolog oncolog total product revenu includ total total incom excl ep tax incom incl stock-bas ep includ stock share outstand ep exclud merger-rel item stock compens upfront-mileston payment item ep cowen
cowen compani
operationsnet long-term prepaid royaltiesprovis account receiv allowancesr gain market secur avail stock-bas compens incom valu conting intang asset issu employe benefit in-process dunreal gain fx forward work capit increas account oper held saleincreas account payabl oper conting incom tax decreas defer cash provid use work cashflow invest activitiesproce sale market secur avail market secur avail sale non-cor invest busi acquisit net cash requiredinvest affili companyoth cashflow invest financ activitiesproce s-t repay s-t issuanc l-t long-term conting exercis common stock option tax benefit share-bas compensationpurchas treasuri adjustmentsnet cashflow financ exchang rate increas decreas cash cash cash equival begin cash equival end cowen
cowen compani
financi year growth revlimid growth revlimid growth revlimid growth growth growth growth hematolog growth growth growth oncolog growth growth growth growth growth world-wide margin oper margin adjust free year growth present valu termin present valu npv per dilut share valu per rate price sensit analysisthursday januari cowen
calcul target price employ one valuat methodolog
includ discount earn analysi discount cash flow analysi net present
valu analysi and/or compar compani analysi analys may may
requir use object measur price-to-earn price-to-sal multipl
well subject measur discount rate
make invest recommend earli stage pre-commerci biotechnolog
compani base upon assess technolog probabl pipelin
success potenti market opportun event success howev
compani lack tradit financi metric believ good
methodolog assign specif target price stock
multipl risk inher invest biotechnolog sector
beyond system risk also clinic regulatori commerci risk addit
biotechnolog compani requir signific amount capit order develop
clinic program capital-rais environ alway chang risk
necessari capit complet develop may readili avail
celgen still highli depend singl drug revlimid revlimid outlook
cloud uncertainti includ relat competit eu regulatori outlook
patent challeng celgen key growth driver abraxan pomalyst still earli
sale trajectori compani long-term earn guidanc somewhat depend
upon success pipelin candid otezla view carri much commerci
